中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

43 records (took 0.041 seconds)

    FLAVIVIRUS VACCINE
    1.
    发明申请
    FLAVIVIRUS VACCINE 有权

    公开(公告)号：US20210069315A1

    公开(公告)日：2021-03-11

    申请号：US16772131

    申请日：2018-12-12

    Applicant: CureVac AG ,  Sanofi Pasteur

    Inventor： Patrick BAUMHOF ,  Wolfgang GROSSE ,  Edith JASNY ,  Thomas KRAMPS ,  Daniel VOSS ,  Julia DANNENMAIER ,  Valérie LECOUTURIER ,  Yves GIRERD-CHAMBAZ

    IPC: A61K39/12 ,  A61P31/14

    Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

    NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION
    4.
    发明申请
    NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION 审中-公开

    公开(公告)号：US20190008954A1

    公开(公告)日：2019-01-10

    申请号：US16004871

    申请日：2018-06-11

    Applicant: CureVac AG

    Inventor： Patrick BAUMHOF

    IPC: A61K39/39 ,  A61K47/64 ,  A61K47/59 ,  A61K47/54 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00

    Abstract: The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.

    OPTIMIZED NUCLEIC ACID MOLECULES
    5.
    发明申请
    OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开

    公开(公告)号：US20180312545A1

    公开(公告)日：2018-11-01

    申请号：US15774423

    申请日：2016-11-09

    Applicant: CureVac AG

    Inventor： Patrick BAUMHOF ,  Susanne RAUCH ,  Aleksandra KOWALCZYK ,  Johannes LUTZ ,  Edith JASNY ,  Benjamin PETSCH ,  Andreas THESS ,  Thomas SCHLAKE ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Sandra LAZZARO ,  Fatma DÖNER ,  Wolfgang GROSSE

    IPC: C07K14/005 ,  C07K14/205 ,  A61K39/145

    CPC classification number: C12N15/00 ,  A61K39/12 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

    Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

    COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
    7.
    发明申请
    COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION 审中-公开
    RNA和阳离子肽的复制用于转移和免疫

    公开(公告)号：US20160367704A1

    公开(公告)日：2016-12-22

    申请号：US15228932

    申请日：2016-08-04

    Applicant: CureVac AG

    Inventor： Mariola FOTIN-MLECZEK ,  Patrick BAUMHOF

    IPC: A61K48/00 ,  C12N9/02

    CPC classification number: A61K48/005 ,  A61K9/0019 ,  A61K38/45 ,  A61K38/4846 ,  A61K39/00 ,  A61K47/61 ,  A61K47/6455 ,  A61K48/0033 ,  A61K48/0041 ,  A61K48/0066 ,  A61K48/0075 ,  A61K2039/53 ,  C07K19/00 ,  C12N9/0069 ,  C12N15/87 ,  C12Y113/12007 ,  C12Y204/01007 ,  C12Y304/21022

    Abstract: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(Lys)m;(His)n;(Om)o;(Xaa)x with the majority of residues being selected from Arg, Lys, His, Om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

    Abstract translation: 本发明涉及复合RNA，其包含与一种或多种寡肽复合的至少一种RNA，其中具有细胞穿透肽（CPP）功能的寡肽具有8至15个氨基酸的长度，并且具有 经验式（Arg）l;（Lys）m;（His）n;（Om）o;（Xaa）x，大部分残基选自Arg，Lys，His，Om。 本发明还涉及用于转染细胞或生物体的方法，从而应用本发明的复合RNA。 此外，本文公开了包含本发明复合RNA的药物组合物和试剂盒，以及本发明的复合RNA用于转染细胞，组织或生物体和/或用于调节，优选诱导或增强免疫应答的用途。

Patent Agency Ranking